Crossmark

QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors

Crossref DOI link: https://doi.org/10.1038/bjc.2014.564

Published Online: 2014-11-06

Published Print: 2015-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ghatalia, P

Je, Y

Kaymakcalan, M D

Sonpavde, G

Choueiri, T K
License Information

License valid from 2014-11-06
More Information

Article History

Received: 4 August 2014

Revised: 15 September 2014

Accepted: 8 October 2014

First Online: 6 November 2014

Competing interests

: TKC is on the advisory board of GSK, Pfizer, Bayer, and obtained a Research grant from Pfizer. The remaining authors declare no conflict of interest.